United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For Adcirca(R)

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2017 -- (Healthcare Sales & Marketing Network) -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivi... Biopharmaceuticals, FDA, Licensing United Therapeutics, Adcirca, tadalafil, Duchenne muscular dystrophy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news